You are here: Home » News-IANS » Health-Medicine
Business Standard

HIV vaccine efficacy study begins in South Africa

IANS  |  Washington 

The first HIV vaccine efficacy study in seven years has begun in to test whether a modified vaccine candidate can provide effective protection against the AIDS virus, the US National Institutes of Health said.

The study -- called HVTN 702 -- aims to enroll 5,400 sexually active men and women aged 18 to 35 years, making it the largest and most advanced HIV vaccine clinical trial to take place in South Africa, Xinhua news agency reported.

"If deployed alongside our current armoury of proven HIV prevention tools, a safe and effective vaccine could be the final nail in the coffin for HIV," said Director of the National Institute of Allergy and Infectious Diseases (NIAID), Anthony Fauci in a statement.

The experimental vaccine regimen being tested in HVTN 702 is based on the one investigated in the RV144 clinical trial in Thailand that was found to be 31.2 per cent effective at preventing HIV infection over the 3.5-year follow-up after vaccination.

The new trial, to be conducted at 15 sites across South Africa, where more than 1,000 people become infected with HIV every day, aims to test whether it will provide greater and more sustained protection than the RV144 regimen.

Volunteers will been randomly assigned to receive either the investigational vaccine regimen or a placebo. All participants will receive a total of five injections over one year, and results are expected in late 2020.

"If an HIV vaccine were found to work in South Africa, it could dramatically alter the course of the pandemic," said HVTN 702 Protocol Chair and President of the South African Medical Research Council Glenda Gray.

--IANS

vgu/

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

HIV vaccine efficacy study begins in South Africa

The first HIV vaccine efficacy study in seven years has begun in South Africa to test whether a modified vaccine candidate can provide effective protection against the AIDS virus, the US National Institutes of Health said.

The first HIV vaccine efficacy study in seven years has begun in to test whether a modified vaccine candidate can provide effective protection against the AIDS virus, the US National Institutes of Health said.

The study -- called HVTN 702 -- aims to enroll 5,400 sexually active men and women aged 18 to 35 years, making it the largest and most advanced HIV vaccine clinical trial to take place in South Africa, Xinhua news agency reported.

"If deployed alongside our current armoury of proven HIV prevention tools, a safe and effective vaccine could be the final nail in the coffin for HIV," said Director of the National Institute of Allergy and Infectious Diseases (NIAID), Anthony Fauci in a statement.

The experimental vaccine regimen being tested in HVTN 702 is based on the one investigated in the RV144 clinical trial in Thailand that was found to be 31.2 per cent effective at preventing HIV infection over the 3.5-year follow-up after vaccination.

The new trial, to be conducted at 15 sites across South Africa, where more than 1,000 people become infected with HIV every day, aims to test whether it will provide greater and more sustained protection than the RV144 regimen.

Volunteers will been randomly assigned to receive either the investigational vaccine regimen or a placebo. All participants will receive a total of five injections over one year, and results are expected in late 2020.

"If an HIV vaccine were found to work in South Africa, it could dramatically alter the course of the pandemic," said HVTN 702 Protocol Chair and President of the South African Medical Research Council Glenda Gray.

--IANS

vgu/

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

HIV vaccine efficacy study begins in South Africa

The first HIV vaccine efficacy study in seven years has begun in to test whether a modified vaccine candidate can provide effective protection against the AIDS virus, the US National Institutes of Health said.

The study -- called HVTN 702 -- aims to enroll 5,400 sexually active men and women aged 18 to 35 years, making it the largest and most advanced HIV vaccine clinical trial to take place in South Africa, Xinhua news agency reported.

"If deployed alongside our current armoury of proven HIV prevention tools, a safe and effective vaccine could be the final nail in the coffin for HIV," said Director of the National Institute of Allergy and Infectious Diseases (NIAID), Anthony Fauci in a statement.

The experimental vaccine regimen being tested in HVTN 702 is based on the one investigated in the RV144 clinical trial in Thailand that was found to be 31.2 per cent effective at preventing HIV infection over the 3.5-year follow-up after vaccination.

The new trial, to be conducted at 15 sites across South Africa, where more than 1,000 people become infected with HIV every day, aims to test whether it will provide greater and more sustained protection than the RV144 regimen.

Volunteers will been randomly assigned to receive either the investigational vaccine regimen or a placebo. All participants will receive a total of five injections over one year, and results are expected in late 2020.

"If an HIV vaccine were found to work in South Africa, it could dramatically alter the course of the pandemic," said HVTN 702 Protocol Chair and President of the South African Medical Research Council Glenda Gray.

--IANS

vgu/

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard